SAB Biotherapeutics (SABS)
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
📉 **NEGATIVE** • Medium confidence analysis (70%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (14%) **Content type:** Clinical